{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:19:55Z","timestamp":1788941995101,"version":"build-2803163510"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver Transpl"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Cystic fibrosis (CF) is an autosomal recessive disease characterized by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). CFTR gene mutations manifest as epithelial cell dysfunction in the airways, biliary tract, pancreas, gut, sweat glands, paranasal sinuses, and genitourinary tract. The clinical manifestations of this dysfunction include respiratory tract infections, bronchiectasis, pancreatic insufficiency, malabsorption, intestinal obstruction, liver disease, and male infertility. The liver disease manifestations of CF can include biliary disease, multilobular cirrhosis, and portal hypertension with and without cirrhosis. Pulmonary disease is the main cause for morbidity and mortality in individuals with CF, and according to the International Society for Heart and Lung Transplantation, CF is the third most common indication for lung transplantation in adults, accounting for 16% of procedures performed. The survival after lung transplantation in individuals with CF continues to improve and is now the highest among end\u2010stage lung diseases requiring transplant. The survival rate at 10\u00a0years is close to 50%. Given the potential presence of liver disease in CF patients undergoing an evaluation for lung transplantation and in lung transplant recipients, it is important to understand the manifestations of liver disease in CF patients and the recommended workup and follow\u2010up. This review aims to discuss the current literature and provide guidance in the management of these patients.<\/jats:p>","DOI":"10.1002\/lt.25496","type":"journal-article","created":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T16:14:28Z","timestamp":1558196068000},"page":"1265-1275","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cystic Fibrosis\u2013Associated Liver Disease in Lung Transplant Recipients"],"prefix":"10.1097","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4962-8838","authenticated-orcid":false,"given":"Jorge","family":"Mallea","sequence":"first","affiliation":[{"name":"Department of Transplantation,Mayo Clinic,Jacksonville,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Bolan","sequence":"additional","affiliation":[{"name":"Department of Radiology,Mayo Clinic,Jacksonville,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherise","family":"Cortese","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology,Mayo Clinic,Jacksonville,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Harnois","sequence":"additional","affiliation":[{"name":"Department of Transplantation,Mayo Clinic,Jacksonville,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"lt25496-bib-0001-20240115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccm.2015.11.002","article-title":"Genetics of cystic fibrosis: clinical implications","volume":"37","year":"2016","journal-title":"Clin Chest Med"},{"key":"lt25496-bib-0002-20240115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","year":"2016","journal-title":"Lancet Respir Med"},{"key":"lt25496-bib-0004-20240115","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"lt25496-bib-0005-20240115","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.510300527","article-title":"Natural history of liver disease in cystic fibrosis","volume":"30","year":"1999","journal-title":"Hepatology"},{"key":"lt25496-bib-0006-20240115","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jhep.2011.03.028","article-title":"Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"lt25496-bib-0007-20240115","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult\u2010onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"lt25496-bib-0008-20240115","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1001\/jama.2009.1295","article-title":"Genetic modifiers of liver disease in cystic fibrosis","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"lt25496-bib-0009-20240115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","year":"2013","journal-title":"J Cyst Fibros"},{"key":"lt25496-bib-0010-20240115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcf.2017.09.012","article-title":"Lumacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del\u2010CFTR","volume":"17","year":"2018","journal-title":"J Cyst Fibros"},{"key":"lt25496-bib-0011-20240115","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"lt25496-bib-0012-20240115","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. chronic medications for maintenance of lung health","volume":"187","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"lt25496-bib-0013-20240115","first-page":"CD008319","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","volume":"10","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"lt25496-bib-0014-20240115","first-page":"CD001021","article-title":"Inhaled anti\u2010pseudomonal antibiotics for long\u2010term therapy in cystic fibrosis","volume":"3","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"lt25496-bib-0015-20240115","first-page":"524","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His\u2010CFTR mutation: a double\u2010blind, randomised controlled trial. Lancet","volume":"3","year":"2015","journal-title":"Respir Med"},{"key":"lt25496-bib-0016-20240115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2010ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"lt25496-bib-0017-20240115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3748\/wjg.v23.i5.763","article-title":"Current and future therapies for inherited cholestatic liver diseases","volume":"23","year":"2017","journal-title":"World J Gastroenterol"},{"key":"lt25496-bib-0018-20240115","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMe1712335","article-title":"CFTR modulator therapy for cystic fibrosis","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"lt25496-bib-0019-20240115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","article-title":"Lumacaftor\/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del\u2010CFTR","volume":"14","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"lt25496-bib-0020-20240115","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2010ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"lt25496-bib-0021-20240115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic fibrosis foundation pulmonary guidelines. use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis","volume":"15","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"lt25496-bib-0022-20240115","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX\u2010659\u2010tezacaftor\u2010ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"lt25496-bib-0023-20240115","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX\u2010445\u2010tezacaftor\u2010ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"lt25496-bib-0024-20240115","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00330-018-5650-5","article-title":"The efficacy of MRI in the diagnostic workup of cystic fibrosis\u2010associated liver disease: a clinical observational cohort study","volume":"29","year":"2019","journal-title":"Eur Radiol"},{"issue":"suppl 2","key":"lt25496-bib-0025-20240115","first-page":"S29","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis\u2010associated liver disease","volume":"10","year":"2011","journal-title":"J Cyst Fibros"},{"key":"lt25496-bib-0026-20240115","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/00365521.2018.1534986","article-title":"Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease","volume":"53","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"lt25496-bib-0028-20240115","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ultrasmedbio.2015.11.011","article-title":"Longitudinal transient elastography measurements used in follow\u2010up for patients with cystic fibrosis","volume":"42","year":"2016","journal-title":"Ultrasound Med Biol"},{"key":"lt25496-bib-0029-20240115","doi-asserted-by":"crossref","first-page":"e0178784","DOI":"10.1371\/journal.pone.0178784","article-title":"Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: results from a prospective longitudinal cohort study","volume":"12","year":"2017","journal-title":"PLoS ONE"},{"key":"lt25496-bib-0030-20240115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOG.0000000000000432","article-title":"Liver disease in patients with cystic fibrosis","volume":"34","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"lt25496-bib-0031-20240115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"lt25496-bib-0032-20240115","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jcf.2016.07.009","article-title":"Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients","volume":"15","year":"2016","journal-title":"J Cyst Fibros"},{"key":"lt25496-bib-0033-20240115","first-page":"CD000222","article-title":"Ursodeoxycholic acid for cystic fibrosis\u2010related liver disease","volume":"9","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"lt25496-bib-0034-20240115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpeds.2016.05.008","article-title":"Long\u2010term ursodeoxycholic acid therapy does not alter lithocholic acid levels in patients with cystic fibrosis with associated liver disease","volume":"177","year":"2016","journal-title":"J Pediatr"},{"key":"lt25496-bib-0035-20240115","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High\u2010dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"lt25496-bib-0036-20240115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High\u2010dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"lt25496-bib-0037-20240115","first-page":"CD008759","article-title":"Platelet count, spleen length, and platelet count\u2010to\u2010spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis","volume":"4","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"lt25496-bib-0038-20240115","first-page":"24","article-title":"Assessment of liver disease in cystic fibrosis","volume":"27","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"lt25496-bib-0039-20240115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MPG.0000000000001423","article-title":"King's variceal prediction score: a novel noninvasive marker of portal hypertension in pediatric chronic liver disease","volume":"64","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"lt25496-bib-0040-20240115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MPG.0000000000001728","article-title":"Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis","volume":"66","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"lt25496-bib-0041-20240115","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.chest.2015.10.040","article-title":"Hepatopulmonary syndrome in patients with cystic fibrosis and liver disease","volume":"149","year":"2016","journal-title":"Chest"},{"key":"lt25496-bib-0043-20240115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jcf.2017.06.008","article-title":"The evolution of lung transplantation for cystic fibrosis: a 2017 update","volume":"16","year":"2017","journal-title":"J Cyst Fibros"},{"key":"lt25496-bib-0044-20240115","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1016\/j.transproceed.2008.08.120","article-title":"Results of lung transplantation in patients with cystic fibrosis","volume":"40","year":"2008","journal-title":"Transplant Proc"},{"key":"lt25496-bib-0045-20240115","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1183\/09031936.00119714","article-title":"A contemporary survival analysis of individuals with cystic fibrosis: a cohort study","volume":"45","year":"2015","journal-title":"Eur Respir J"},{"key":"lt25496-bib-0046-20240115","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201501-0126OC","article-title":"Effects of recipient age and diagnosis on health\u2010related quality\u2010of\u2010life benefit of lung transplantation","volume":"192","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"lt25496-bib-0047-20240115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ccm.2015.11.008","article-title":"Lung transplantation for cystic fibrosis","volume":"37","year":"2016","journal-title":"Clin Chest Med"},{"key":"lt25496-bib-0048-20240115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1399-0012.2010.01395.x","article-title":"Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis\u2010associated liver cirrhosis","volume":"26","year":"2012","journal-title":"Clin Transplant"},{"key":"lt25496-bib-0049-20240115","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/lt.23389","article-title":"Pulmonary function in individuals who underwent liver transplantation: from the US cystic fibrosis foundation registry","volume":"18","year":"2012","journal-title":"Liver Transpl"},{"key":"lt25496-bib-0050-20240115","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1097\/TXD.0000000000000785","article-title":"Single\u2010center long\u2010term analysis of combined liver\u2010lung transplant outcomes","volume":"4","year":"2018","journal-title":"Transplant Direct"},{"key":"lt25496-bib-0051-20240115","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.healun.2018.07.020","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty\u2010fifth adult lung and heart\u2010lung transplant report\u20102018; focus theme: multiorgan transplantation","volume":"37","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"lt25496-bib-0052-20240115","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/01.tp.0000266067.44499.07","article-title":"Lower incidence of bronchiolitis obliterans in pediatric liver\u2010lung transplant recipients with cystic fibrosis","volume":"83","year":"2007","journal-title":"Transplantation"},{"key":"lt25496-bib-0053-20240115","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.jtcvs.2011.01.056","article-title":"Does simultaneous lung\u2010liver transplantation provide an immunologic advantage compared with isolated lung transplantation?","volume":"141","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"lt25496-bib-0054-20240115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1034\/j.1600-0528.2002.017419.x","article-title":"Immunological tolerance\u2013the liver effect","volume":"174","year":"2000","journal-title":"Immunol Rev"},{"key":"lt25496-bib-0055-20240115","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.transproceed.2012.02.033","article-title":"Survival of cystic fibrosis patients undergoing liver and liver\u2010lung transplantations","volume":"45","year":"2013","journal-title":"Transplant Proc"},{"key":"lt25496-bib-0056-20240115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/lt.22240","article-title":"Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data","volume":"17","year":"2011","journal-title":"Liver Transpl"},{"key":"lt25496-bib-0057-20240115","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1600-6143.2011.03904.x","article-title":"Long\u2010term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"lt25496-bib-0058-20240115","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/ejcts\/ezy217","article-title":"The liver\u2010first approach for combined lung and liver transplantation","volume":"54","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"lt25496-bib-0059-20240115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcf.2013.12.010","article-title":"Simultaneous liver\u2010pancreas transplantation for cystic fibrosis\u2010related liver disease: a multicenter experience","volume":"13","year":"2014","journal-title":"J Cyst Fibros"},{"key":"lt25496-bib-0060-20240115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jcf.2017.05.004","article-title":"Combined lung\u2010liver\u2010pancreas transplantation in a recipient with cystic fibrosis","volume":"17","year":"2018","journal-title":"J Cyst Fibros"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lt.25496","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201908000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T01:34:07Z","timestamp":1705282447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201908000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.25496","relation":{},"ISSN":["1527-6465","1527-6473"],"issn-type":[{"value":"1527-6465","type":"print"},{"value":"1527-6473","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]}}}